Philip Morris

Philip Morris raised its Q3 earnings forecast to EPS of $2.29–2.34, above the consensus estimate of $2.25, which pushed the stock up about 2.1% intraday. The company also lifted its full-year adjusted EPS guidance to $8.35–8.50 and expects a positive currency effect of around $0.24 per share. Analysts then raised price targets to a range of $205–225, citing the defensive business model and the expansion of smoke-free products as supporting factors. » Mere på de.investing.com

Philip Morris International has entered into a contract manufacturing agreement for conventional cigarettes with Philip Morris USA, an Altria company. Initial deliveries are expected to begin in early 2027, subject to operational readiness and regulatory requirements. The company does not expect a material impact on 2026 financial results and emphasizes that it does not sell—and does not plan to sell—conventional cigarettes in the U.S. Both companies will remain operationally independent and aim to better utilize their manufacturing capacity and expertise. » Mere på de.investing.com

The FDA has granted marketing authorization to Swedish Match USA, a subsidiary of Philip Morris, for 11 ZYN ULTRA nicotine pouches. Ten products with 9 mg (various flavors) and one 11 mg variant were approved; additional 11 mg variants are still under review. Philip Morris expects this to strengthen ZYN's position in the US, is expanding domestic production, and is responding to competitive pressure from brands like Velo Plus. » Mere på de.investing.com